$BIIB News

Can Biogen Score Another Win In Alzheimer's Disease?

Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details

Truist Securities Upgrades Biogen to Buy, Raises Price Target to $235

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

Biogen's Q2 2026 Earnings: What to Expect

Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $222

Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $242

Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now

BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers

Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?

Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026

Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Respectively

Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?

Biogen trims Apellis pipeline and R&D team after $5.6bn takeover